



# Human Osteoprotegerin ELISA Kit

## User Manual

**Catalog # CEK1300**

(Version 1.1A)

Sandwich Enzyme-Linked Immunosorbent Assay for Quantitative  
Detection of Human Osteoprotegerin Concentrations in Cell Culture  
Supernatants, Serum, Plasma, Urine.

**For research use only. Not for diagnostic or therapeutic procedures.**

I. INTRODUCTION.....	2
II. ASSAY PRINCIPLES.....	3
III. KIT COMPONENTS.....	4
IV. STORAGE AND STABILITY.....	4
V. MATERIALS REQUIRED BUT NOT PROVIDED.....	5
VI. HEALTH AND SAFETY PRECAUTIONS.....	5
VII. REAGENT PREPARATION.....	6
VIII. ASSAY PROCEDURE.....	9
IX. ASSAY PROCEDURE SUMMARY.....	11
X. TYPICAL DATA.....	12
XI. SENSITIVITY.....	12
XII. SPECIFICITY.....	12
XIII. CROSS REACTIVITY.....	13
XIV. REFERENCES.....	13
XV. TROUBLESHOOTING GUIDE.....	14
XVI. TECHNICAL SUPPORT.....	15
XVII. NOTES.....	15

## I. INTRODUCTION

Osteoprotegerin (OPG) is identical to osteoclastogenesis inhibitory factor (OCIF), a soluble member of the tumor-necrosis factor receptor family that inhibits osteoclastogenesis. OPG is considered to play an important role in the regulation of bone resorption by modifying osteoclast differentiation.<sup>2</sup> Osteoprotegerin is an independent risk factor for the progression of atherosclerosis and onset of cardiovascular disease. It can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity. OPG system may play a critical role in the development of osteolytic bone disease in multiple myeloma and that targeting this system may have therapeutic potential. OPG also plays a role in the vascular system.

## II. ASSAY PRINCIPLES

The Cohesion Bioscience Human Osteoprotegerin ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of Human Osteoprotegerin in Cell Culture Supernatants, Serum, Plasma, Urine. This assay employs an antibody specific for Human Osteoprotegerin coated on a 96-well plate. Standards and samples are pipetted into the wells and Osteoprotegerin present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-Human Osteoprotegerin antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of Osteoprotegerin bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.

### III. KIT COMPONENTS

Component	Volume
96-well Plate Coated With Anti-Human Osteoprotegerin Antibody	8 wells x 12 Strips
Human Osteoprotegerin Standard	10 ng x 2
Biotin-Labeled Detection Antibody (100X)	120 $\mu$ l
Streptavidin-HRP (100X)	120 $\mu$ l
Standard/Sample Diluent	30 ml
Detection Antibody Diluent	12 ml
Streptavidin-HRP Diluent	12 ml
Wash Buffer (20X)	30 ml
TMB Substrate Solution	12 ml
Stop Solution	12 ml
Plate Adhesive Strips	3 Strips
Technical Manual	1 Manual

### IV. STORAGE AND STABILITY

All kit components are stable at 2 to 8 °C. Standard (recombinant protein) should be stored at -20 °C or -80 °C (recommended at -80 °C) after reconstitution. Opened Microplate Wells or reagents may be store for up to 1 month at 2 to 8 °C. Return unused wells to the pouch containing desiccant pack, reseal along entire edge.

Note: the kit can be used within one year if the whole kit is stored at -20 °C. Avoid repeated freeze-thaw cycles.

## **V. MATERIALS REQUIRED BUT NOT PROVIDED**

1. Microplate reader capable of measuring absorbance at 450 nm.
2. Adjustable pipettes and pipette tips to deliver 2 µl to 1 ml volumes.
3. Adjustable 1-25 ml pipettes for reagent preparation.
4. 100 ml and 1 liter graduated cylinders.
5. Absorbent paper.
6. Distilled or deionized water.
7. Computer and software for ELISA data analysis.
8. Tubes to prepare standard or sample dilutions.

## **VI. HEALTH AND SAFETY PRECAUTIONS**

1. Reagents provided in this kit may be harmful if ingested, inhaled or absorbed through the skin. Please carefully review the MSDS for each reagent before conducting the experiment.
2. Stop Solution contains 2 N Sulfuric Acid ( $H_2SO_4$ ) and is an extremely corrosive agent. Please wear proper eye, hand and face protection when handling this material. When the experiment is finished, be sure to rinse the plate with copious amounts of running water to dilute the Stop Solution prior to disposing the plate.

## VII. REAGENT PREPARATION

### 1. Sample Preparation

Store samples to be assayed within 24 hours at 2-8°C. For long-term storage, aliquot and freeze samples at -20°C. Avoid repeated freeze-thaw cycles.

**Cell culture supernates:** Remove particulates by centrifugation, assay immediately or aliquot and store samples at -20°C.

**Serum:** Allow the serum to clot in a serum separator tube (about 4 hours) at room temperature. Centrifuge at approximately 1000 X g for 15 minutes. Analyze the serum immediately or aliquot and store samples at -20°C.

**Plasma:** Collect plasma using heparin or EDTA as an anticoagulant. Centrifuge for 15 minutes at 1500 X g within 30 minutes of collection. Assay immediately or aliquot and store samples at -20°C.

**Cell Lysates:** Collect cells and rinse cells with PBS. Homogenize and lyse cells thoroughly in lysate solution. Centrifuge cell lysates at approximately 10000 X g for 5 minutes to remove debris. Aliquots of the cell lysates were removed and assayed.

**Bone Tissue:** Extract demineralized bone samples in 4 M Guanidine-HCl and protease inhibitors. Dissolve the final sample in 2 M Guanidine-HCl.

**Tissue Homogenates:** The preparation of tissue homogenates will vary depending upon tissue type. Rinse tissue with 1X PBS to remove excess blood, homogenized in 20 mL of 1X PBS and stored overnight at  $\leq -20$  °C. After two freeze-thaw cycles were performed to break the cell membranes, the homogenates were centrifuged for 5 minutes at 5000 x g. The supernate was removed immediately and assayed.

Alternatively, aliquot and store samples at  $\leq -20$  °C.

**Note:** Some lysis buffer, such as RIPA can not be used. Some components will affect the binding.

**Urine:** Urinary samples should be cleared by centrifugation and then can be used directly without dilution. Storage at -20°C.

## 2. Human Osteoprotegerin Standard Preparation

Reconstitute the lyophilized Human Osteoprotegerin Standard by adding 1 ml of Standard/Sample Diluent to make the 10000 pg/ml standard stock solution. Allow solution to sit at room temperature for 5 minutes, then gently vortex to mix completely. Use within one hour of reconstituting. Two tubes of the standard (10 ng per tube) are included in each kit. Use one tube for each experiment.

Perform 2-fold serial dilutions of the top standards to make the standard curve within the range of this assay (93.7 pg/ml - 6000 pg/ml) as below. Standard/Sample Dilution Buffer serves as the zero standard (0 pg/ml).

Standard	Add	Into
6000 pg/ml	600 µl of the Standard (10000 pg/ml)	400 µl of the Standard/Sample Diluent
3000 pg/ml	500 µl of the Standard (6000 pg/ml)	500 µl of the Standard/Sample Diluent
1500 pg/ml	500 µl of the Standard (3000 pg/ml)	500 µl of the Standard/Sample Diluent
750 pg/ml	500 µl of the Standard (1500 pg/ml)	500 µl of the Standard/Sample Diluent
375 pg/ml	500 µl of the Standard (750 pg/ml)	500 µl of the Standard/Sample Diluent
187.5 pg/ml	500 µl of the Standard (375 pg/ml)	500 µl of the Standard/Sample Diluent
93.75 pg/ml	500 µl of the Standard (187.5 pg/ml)	500 µl of the Standard/Sample Diluent
0 ng/ml	1 ml of the Standard/Sample Diluent	

**Note:** The standard solutions are best used within 2 hours. The 10000 pg/ml standard solution should be stored at 4°C for up to 12 hours, or at -20°C for up to 48 hours. Avoid repeated freeze-thaw cycles.

## 3. Biotin-Labeled Detection Antibody Working Solution Preparation

The Biotin-Labeled Detection Antibody should be diluted in 1:100 with the Detection Antibody Diluent and mixed thoroughly. The solution should be prepared no more than 2 hours prior to the experiment.

## 4. Streptavidin-HRP Working Solution Preparation



The Streptavidin-HRP should be diluted in 1:100 with the Streptavidin-HRP Diluent and mixed thoroughly. The solution should be prepared no more than 1 hour prior to the experiment.

#### 5. Wash Buffer Working Solution Preparation

Pour entire contents (30 ml) of the Wash Buffer Concentrate into a clean 1,000 ml graduated cylinder. Bring final volume to 600 ml with glass-distilled or deionized water (1:20).

## VIII. ASSAY PROCEDURE

The Streptavidin-HRP Working Solution and TMB Substrate Solution must be kept warm at 37°C for 30 minutes before use. When diluting samples and reagents, they must be mixed completely and evenly. Standard detection curve should be prepared for each experiment. The user will decide sample dilution fold by crude estimation of protein amount in samples.

1. Add 100  $\mu$ l of each standard and sample into appropriate wells.
2. Cover well and incubate for 90 minutes at room temperature or over night at 4°C with gentle shaking.
3. Remove the cover, discard the solution and wash plate 3 times with Wash Buffer Working Solution, and each time let Wash Buffer Working Solution stay in the wells for 1 - 2 minutes. Blot the plate onto paper towels or other absorbent material. Do NOT let the wells completely dry at any time.
4. Add 100  $\mu$ l of Biotin-Labeled Detection Antibody Working Solution into each well and incubate the plate at 37°C for 60 minutes.
5. Wash plate 3 times with Wash Buffer Working Solution, and each time let Wash Buffer Working Solution stay in the wells for 1 - 2 minutes. Discard the Wash Buffer Working Solution and blot the plate onto paper towels or other absorbent material.
6. Add 100  $\mu$ l of Streptavidin-HRP Working Solution into each well and incubate the plate at 37°C for 45 minutes.
7. Wash plate 5 times with Wash Buffer Working Solution, and each time let wash buffer stay in the wells for 1 - 2 minutes. Discard the wash buffer and blot the plate onto paper towels or other absorbent material.
8. Add 100  $\mu$ l of TMB Substrate Solution into each well and incubate plate at 37°C in dark for 10-20 minutes.
9. Add 100  $\mu$ l of Stop Solution into each well. The color changes into yellow immediately.

10. Read the O.D. absorbance at 450nm in a microplate reader within 30 minutes after adding the Stop Solution.

For calculation, (the relative O.D.450) = (the O.D.450 of each well) - (the O.D.450 of Zero well). The standard curve can be plotted as the relative O.D.450 of each standard solution (Y) vs. the respective concentration of the standard solution (X). The concentration of the samples can be interpolated from the standard curve.


**Note:** If the samples measured were diluted, multiply the dilution factor to the concentrations from interpolation to obtain the concentration before dilution.

**IX. ASSAY PROCEDURE SUMMARY**

- 
- Prepare all reagents, samples and standards
  - Add 100  $\mu$ l Standard or Sample
  - Wash plate 3 times with Wash Buffer Working Solution
  - Add 100  $\mu$ l Biotin-Labeled Detection Antibody Working Solution
  - Wash plate 3 times with Wash Buffer Working Solution
  - Add 100  $\mu$ l Streptavidin-HRP Working Solution
  - Wash plate 5 times with Wash Buffer Working Solution
  - Add 100  $\mu$ l TMB Substrate Solution
  - Add 100  $\mu$ l Stop Solution
  - Read the plate at 450nm

## X. TYPICAL DATA

The standard curve is for demonstration only. A standard curve must be run with each assay.



## XI. SENSITIVITY

The minimum detectable dose of Human Osteoprotegerin is typically less than 5 pg/ml.

## XII. SPECIFICITY

The Human Osteoprotegerin ELISA Kit allows for the detection and quantification of endogenous levels of natural and/or recombinant Human Osteoprotegerin proteins within the range of 93.7 pg/ml - 6000 pg/ml.

### **XIII. CROSS REACTIVITY**

No detectable cross-reactivity with other relevant proteins.

### **XIV. REFERENCES**

1. Yasuda, H.; Shima, N.; Nakagawa, N.; Mochizuki, S. I.; Yano, K.; Fujise, N.; Sato, Y.; Goto, M.; Yamaguchi, K.; Kuriyama, M.; Kanno, T.; Murakami, A.; Tsuda, E.; Morinaga, T.; Higashio, K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. *Endocrinology* 139: 1329-1337, 1998.
2. Ohmori, H.; Makita, Y.; Funamizu, M.; Hirooka, K.; Hosoi, T.; Orimo, H.; Suzuki, T.; Ikari, K.; Nakajima, T.; Inoue, I.; Hata, A. Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis. *J. Hum. Genet.* 47: 400-406, 2002.
3. Kiechl, S.; Schett, G.; Wenning, G.; Redlich, K.; Oberhollenzer, M.; Mayr, A.; Santer, P.; Smolen, J.; Poewe, W.; Willeit, J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. *Circulation* 109: 2175-2180, 2004.
4. Simonet, W. S.; Lacey, D. L.; Dunstan, C. R.; Kelley, M.; Chang, M. -S.; Luthy, R.; Nguyen, H. Q.; Wooden, S.; Bennett, L.; Boone, T.; Shimamoto, G.; DeRose, M.; and 19 others. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Cell* 89: 309-319, 1997.
5. Croucher, P. I.; Shipman, C. M.; Lippitt, J.; Perry, M.; Asosingh, K.; Hijzen, A.; Brabbs, A. C.; van Beek, E. J. R.; Holen, I.; Skerry, T. M.; Dunstan, C. R.; Russell, G. R.; Van Camp, B.; Vanderkerken, K. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. *Blood* 98: 3534-3540, 2001.

## XV. TROUBLESHOOTING GUIDE

Problem	Possible Cause	Solution
High signal and background in all wells	• Insufficient washing	• Increase number of washes • Increase time of soaking between in wash
	• Too much Streptavidin-HRP	• Check dilution, titration
	• Incubation time too long	• Reduce incubation time
	• Development time too long	• Decrease the incubation time before the stop solution is added
No signal	• Reagent added in incorrect order, or incorrectly prepared	• Review protocol
	• Standard has gone bad (If there is a signal in the sample wells)	• Check the condition of stored standard
	• Assay was conducted from an incorrect starting point	• Reagents allows to come to 20 - 30 °C before performing assay
Too much signal-whole plate turned uniformly blue	• Insufficient washing-unbound Streptavidin-HRP remaining	• Increase number of washes Carefully
	• Too much Streptavidin-HRP	• Check dilution
	• Plate sealer or reservoir reused, resulting in presence of residual Streptavidin-HRP	• Use fresh plate sealer and reagent reservoir for each step
Standard curve achieved but poor discrimination between point	• Plate not developed long enough	• Increase substrate solution incubation time
	• Improper calculation of standard curve dilution	• Check dilution, make new standard curve
No signal when a signal is expected, but standard curve looks fine	• Sample matrix is masking detection	• More diluted sample Recommended
Samples are reading too high, but standard curve is fine	• Samples contain protein levels above assay range	• Dilute samples and run Again
Edge effect	• Uneven temperature around work surface	• Avoid incubating plate in areas where environmental conditions vary • Use plate sealer

## **XVI. TECHNICAL SUPPORT**

For troubleshooting, information or assistance, please go online to [www.cohesionbio.com](http://www.cohesionbio.com) or contact us at [techsupport@cohesionbio.com](mailto:techsupport@cohesionbio.com)

### **COHESION BIOSCIENCES LIMITED**

FLAT32 ADVENTURES COURT

12 NEWPORT AVENUE

LONDON, E14 2DN, UK

Website: [www.cohesionbio.com](http://www.cohesionbio.com)

Email: [order@cohesionbio.com](mailto:order@cohesionbio.com)

[techsupport@cohesionbio.com](mailto:techsupport@cohesionbio.com)

[custom@cohesionbio.com](mailto:custom@cohesionbio.com)

## **XVII. NOTES**